Recovery peptides are studied for tissue repair, angiogenesis, anti-inflammatory effects and wound healing. BPC-157 and TB-500 dominate the recovery conversation, while the copper peptide GHK-Cu is central to skin and collagen remodeling. PeptideXR examines what the evidence actually supports — and where the popular claims outrun the data.
Profiles
- AHK-Cu (Alanyl-Histidyl-Lysine + Copper): Mechanism, Benefits & Research Evidence
- BPC-157 (pentadecapeptide): Mechanism, Benefits & Research Evidence
- GHK-Cu (Copper Tripeptide-1): Mechanism, Benefits & Research Evidence
- GLOW blend (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg): Mechanism, Benefits & Research Evidence
- KLOW blend (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg): Mechanism, Benefits & Research Evidence
- KPV (Lys-Pro-Val tripeptide, alpha-MSH C-terminus): Mechanism, Benefits & Research Evidence
- TB-500 / Thymosin Beta-4 (TB4): Mechanism, Benefits & Research Evidence
Comparisons
Questions & Evidence
- How does GHK-Cu interact with the wound-healing senescence-associated secretory phenotype (SASP), and could topical GHK-Cu actually accelerate senescence in some skin cell populations via copper-mediated oxidative stress?
- If GHK-Cu's transcriptomic effects ("regulates 4,000 genes") were obtained at supraphysiological concentrations in vitro, what fraction of marketed topical creams could plausibly reproduce any of them on intact human skin?
- If alopecia areata is principally a JAK-STAT-driven autoimmune disease, what is the actual mechanistic basis for any peptide (GHK-Cu, copper tripeptide, thymulin) producing regrowth — or are users just observing telogen effluvium recovery from unrelated stress reduction?
- If the most-cited BPC-157 healing effects come almost entirely from one lab's rodent studies, what does that imply about the actual evidence base behind the most popular biohacker peptide on the market?
- If we modeled the peptide industry like the early supplement industry (1990s pre-DSHEA), where in the maturation curve is GHK-Cu cosmetic e-commerce in Romania, and what does that predict for next-3-year regulatory pressure?
- If we treated peptide self-experimentation forums as a distributed clinical trial, what statistical adjustments (selection bias, attrition censoring, publication bias) would be needed to extract a credible effect estimate for BPC-157 on tendinopathy?
- Most practitioners assume oral BPC-157 survives gastric transit because Sikiric's papers say so — but if the pharmacokinetic studies used to prove this have never been independently replicated in humans, are oral protocols just placebo with extra steps?
- What is the actual molecular identity of BPC-157's receptor — and given that after 30 years no one has cleanly identified one, does that suggest its effects are mediated by non-specific NO/eNOS modulation rather than a discrete signaling pathway?
- What is the mechanistic relationship between BPC-157's claimed angiogenic effects and VEGFR2 signaling, and could that same mechanism plausibly accelerate occult tumor growth in users with undiagnosed neoplasia?
- What is the precise molecular reason GHK-Cu loses activity in many topical formulations within weeks, and which carrier systems (liposomal, peptide-stabilized, niosomal) actually preserve the Cu²⁺-tripeptide complex under EU cosmetic shelf-life conditions?
- Why does GHK-Cu's copper transport function appear necessary for some of its effects (collagen synthesis) but not others (gene regulation), and what does that imply about cosmetic formulations that omit copper coordination?